156 related articles for article (PubMed ID: 22961216)
21. The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.
Jung JY; Kim HY; Han B; Choi DR; Zang DY; Kim HJ
Biomed Res Int; 2014; 2014():237698. PubMed ID: 24995276
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib.
Tariman JD; Lemoine C
Clin J Oncol Nurs; 2003; 7(6):687-9. PubMed ID: 14705489
[No Abstract] [Full Text] [Related]
24. Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma.
Paiva CM; Kurtis B; Mekki M; Newman MA; Singhal S; Lacouture ME
Ann Oncol; 2007 Oct; 18(10):1744-5. PubMed ID: 17890215
[No Abstract] [Full Text] [Related]
25. Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma.
Beysel S; Yeğın ZA; Yağci M
Turk J Gastroenterol; 2010 Jun; 21(2):197-8. PubMed ID: 20872342
[No Abstract] [Full Text] [Related]
26. Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.
Yamaguchi T; Sasaki M; Itoh K
Jpn J Clin Oncol; 2012 Jul; 42(7):637-9. PubMed ID: 22628610
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib: 3 deaths following intrathecal injection.
Prescrire Int; 2012 Sep; 21(130):214. PubMed ID: 23016258
[No Abstract] [Full Text] [Related]
28. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report.
Tanaka H; Sakuma I; Hashimoto S; Takeda Y; Sakai S; Takagi T; Shimura T; Nakaseko C
J Clin Exp Hematop; 2012; 52(1):67-9. PubMed ID: 22706534
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib plus melphalan and prednisone for multiple myeloma.
Tsubokura M; Kami M; Komatsu T
N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090031
[No Abstract] [Full Text] [Related]
30. Does bortezomib induce de facto varicella zoster virus reactivation in patients with multiple myeloma?
Dasanu CA; Alexandrescu DT
J Clin Oncol; 2009 May; 27(13):2293-4; author reply 2294-6. PubMed ID: 19307496
[No Abstract] [Full Text] [Related]
31. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
Wang HH; Tsui J; Wang XY; Liu SS; Li J
Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
[No Abstract] [Full Text] [Related]
32. The impact of bortezomib on the risk of thrombosis in multiple myeloma.
Connolly G
Leuk Res; 2011 Feb; 35(2):145-6. PubMed ID: 20952063
[No Abstract] [Full Text] [Related]
33. Hyperlipidemia in a myeloma patient after bortezomib treatment.
Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
[No Abstract] [Full Text] [Related]
34. [Effect of Velcade combined with Dexamethasone on multiple myeloma].
He Q; Zhao X; He Y; Tan D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):864-7. PubMed ID: 20818081
[TBL] [Abstract][Full Text] [Related]
35. The safety and efficacy of bortezomib in relapsed multiple myeloma.
Jagannath S
Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
[No Abstract] [Full Text] [Related]
36. Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.
Morita R; Hashino S; Shirai S; Fujita N; Onozawa M; Kahata K; Kondo T; Imamura M; Asaka M
Int J Hematol; 2008 Sep; 88(2):248-250. PubMed ID: 18636313
[No Abstract] [Full Text] [Related]
37. Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
Honton B; Despas F; Dumonteil N; Rouvellat C; Roussel M; Carrie D; Galinier M; Montastruc JL; Pathak A
Fundam Clin Pharmacol; 2014 Jun; 28(3):349-52. PubMed ID: 23781941
[TBL] [Abstract][Full Text] [Related]
38. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
[TBL] [Abstract][Full Text] [Related]
39. [Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].
Koda Y; Mori T; Shimizu T; Kato J; Yamane A; Sadahira K; Tsukada Y; Yokoyama K; Hashimoto N; Hattori Y; Okamoto S
Rinsho Ketsueki; 2012 Aug; 53(8):760-4. PubMed ID: 22975816
[TBL] [Abstract][Full Text] [Related]
40. Subcutaneous bortezomib: in multiple myeloma.
Hoy SM
Drugs; 2013 Jan; 73(1):45-54. PubMed ID: 23338539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
